52.6% Steroid-Free: aTyr's Efzofitimod Shows Promise in Largest-Ever Sarcoidosis
aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint!-->…